Insider · CIK 0001297000
Denise Scots-Knight
Files at MREO (Mereo BioPharma Group plc), ELAN (Elanco Animal Health Inc). First filing -, latest -.
In brief
Denise Scots-Knight files SEC Form 4 as director and CEO at MREO (Mereo BioPharma Group plc), and also at ELAN (Elanco Animal Health Inc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Denise Scots-Knight has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | ELAN Elanco Animal Health Inc | AGrant or award Common Stock | +4,678 | $0.00 | $0 | 93,392 | May 26, 2026 |
| May 21, 2026 | ELAN Elanco Animal Health Inc | AGrant or award Common Stock | +12,196 | $0.00 | $0 | 105,588 | May 26, 2026 |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +1,035,000 | $0.00 | $0 | 1,035,000 | Feb 2, 2026 |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +345,000 | $0.00 | $0 | 345,000 | Feb 2, 2026 |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +480,000 | $0.00 | $0 | 480,000 | Feb 2, 2026 |
| Nov 28, 2025 | ELAN Elanco Animal Health Inc | AGrant or award Common Stock | +10,314 | $0.00 | $0 | 88,714 | Dec 2, 2025 |
| Nov 29, 2024 | ELAN Elanco Animal Health Inc | AGrant or award Common Stock | +18,169 | $0.00 | $0 | 78,400 | Dec 3, 2024 |
Questions about Denise Scots-Knight
Answered from the filings on this page, as of the latest one.
Is Denise Scots-Knight buying or selling?
Denise Scots-Knight has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Denise Scots-Knight's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Denise Scots-Knight has 0.
Where does Denise Scots-Knight file Form 4?
Denise Scots-Knight has filed Form 4 at MREO (Mereo BioPharma Group plc) as Chief Executive Officer; ELAN (Elanco Animal Health Inc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.